obesity, Novo Nordisk and type 2 diabetes
The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...
Professor Arne Astrup is also involved in project to change widely-accepted definition of ultra-processed food ...
The Foundation announced the project in February, saying in a post on its website that has since been edited that it was time ...
Brazil's National Health Surveillance Agency (Anvisa) has approved the drug Awiqli, produced by the pharmaceutical company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results